<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022173</url>
  </required_header>
  <id_info>
    <org_study_id>13412</org_study_id>
    <nct_id>NCT05022173</nct_id>
  </id_info>
  <brief_title>Helmet NIV in Acute Respiratory Failure</brief_title>
  <acronym>HELMET</acronym>
  <official_title>Helmet NIV Versus Facemask NIV in Acute Respiratory Failure: A Pilot Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive ventilation (NIV) is a form of respiratory support that has been shown to&#xD;
      prevent invasive mechanical ventilation and reduce mortality. This study will investigate the&#xD;
      feasibility of performing a larger study examining whether a new modality of NIV, the helmet,&#xD;
      is superior to the current face mask in reducing mortality in patients with sudden&#xD;
      respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consent Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients or SDMs approached for consent who give consent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients recruited to the study per centre</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol adherence percentage</measure>
    <time_frame>1 year</time_frame>
    <description>Adherence to pre-specified fixed protocol on how helmet interface is implemented (settings, weaning etc.) Any protocol deviations will be recorded and marked as protocol non-adherence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endotracheal intubation</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients requiring endotracheal intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients who die in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>60 days</time_frame>
    <description>Number of patients who die in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Censored at 28 days</time_frame>
    <description>Number of days that each patient spends in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Censored at 60 days</time_frame>
    <description>Number of days that each patients spends in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-invasive ventilation</measure>
    <time_frame>Censored at 28 days</time_frame>
    <description>Number of days that patient receives non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive ventilation</measure>
    <time_frame>Censored at 28 days</time_frame>
    <description>Number of days that patient receives invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Any complications related to NIV use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort</measure>
    <time_frame>28 days</time_frame>
    <description>Patient comfort with non-invasive ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Helmet NIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the intervention arm will receive NIV through a phthalate free helmet (CaStar, STARMED) via an ICU ventilator in pressure support (PS) mode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facemask NIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the control arm will be randomized to the traditional facemask interface. The facemask group will use the same ICU ventilator being used for the helmet group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet Non-Invasive Ventilation</intervention_name>
    <description>The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.</description>
    <arm_group_label>Helmet NIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Facemask Non-Invasive Ventilation</intervention_name>
    <description>The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.</description>
    <arm_group_label>Facemask NIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) patients who are admitted to the adult ICU&#xD;
&#xD;
          -  2) deemed to require NIV, as per the clinical team, for acute respiratory failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) with impending cardiac arrest or need for intubation&#xD;
&#xD;
          -  2) Glasgow coma scale &lt;9&#xD;
&#xD;
          -  3) tracheostomy or upper airway obstruction&#xD;
&#xD;
          -  4) elevated intracranial pressure&#xD;
&#xD;
          -  5) untreated pneumothorax&#xD;
&#xD;
          -  6) who refuse endotracheal intubation (do not intubate order documented)&#xD;
&#xD;
          -  7) facial trauma&#xD;
&#xD;
          -  8) are unable to wear the helmet or facemask&#xD;
&#xD;
          -  9) who use NIV chronically&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bram Rochwerg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dipayan Chaudhuri, MD</last_name>
    <phone>9055212100</phone>
    <email>dipayan.chaudhuri@medportal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Dipayan Chaudhuri, MD</last_name>
      <email>dipayan_c@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Bram Rochwerg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-invasive ventilation</keyword>
  <keyword>Helmet non-invasive ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

